Somewhat Positive Press Coverage Somewhat Unlikely to Impact Fennec Pharmaceuticals (NASDAQ:FENC) Share Price

News coverage about Fennec Pharmaceuticals (NASDAQ:FENC) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Fennec Pharmaceuticals earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave news headlines about the company an impact score of 44.3771188322318 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Several research analysts have recently issued reports on the company. Laidlaw assumed coverage on Fennec Pharmaceuticals in a research note on Wednesday, November 29th. They set a “buy” rating and a $22.00 price target for the company. ValuEngine downgraded Fennec Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, December 19th.

Fennec Pharmaceuticals (FENC) opened at $9.26 on Wednesday. The stock has a market capitalization of $150.35, a price-to-earnings ratio of -23.15 and a beta of 0.22. Fennec Pharmaceuticals has a one year low of $8.00 and a one year high of $13.95.

Fennec Pharmaceuticals (NASDAQ:FENC) last released its quarterly earnings results on Monday, November 13th. The company reported ($0.15) earnings per share (EPS) for the quarter. During the same period last year, the business earned ($0.04) earnings per share.

In other news, major shareholder Spa Essetifin bought 294,115 shares of the business’s stock in a transaction that occurred on Tuesday, December 12th. The stock was purchased at an average price of $8.50 per share, with a total value of $2,499,977.50. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 10.70% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first posted by BBNS and is the property of of BBNS. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://baseballnewssource.com/markets/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-fennec-pharmaceuticals-fenc-share-price/1822403.html.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, formerly Adherex Technologies Inc, is a biopharmaceutical company focused on cancer therapeutics. The Company’s lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children.

Insider Buying and Selling by Quarter for Fennec Pharmaceuticals (NASDAQ:FENC)

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.